Bristol-Myers Squibb Co. (BMY) has sought FDA approval for its CAR T cell therapy Breyanzi for yet another indication, and a decision is due on March 14, 2024.The proposed expanded indication is to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received a prior Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i). If approved, Breyanzi would be the first and only CAR T cell therapy available for patients with relapsed or refractory CLL or SLL after prior therapy with targeted agents.The drug is already approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.The global annual sales of Breyanzi were $364 million in 2023 compared to $182 million in 2022.BMY closed Tuesday's (Feb.27, 2024) trading at $50.51, down 0.02%.